LYTGOBI (FUTIBATINIB) tablet

Select patients for the treatment of unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma with LYTGOBI based on the presence of an FGFR2 gene fusion or rearrangement [see Clinical Studies (14.1)]. An FDA-approved test for detection of FGFR2 gene fusions or other rearrangements in patients with unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma for selecting patients for treatment with LYTGOBI is not available.

The recommended dosage of LYTGOBI is 20 mg (five 4 mg tablets or one 16 mg and one 4 mg tablet) taken orally once daily until disease progression or unacceptable toxicity occurs.

Take LYTGOBI with or without food at approximately the same time each day [see Clinical Pharmacology (12.3)].

Swallow tablets whole. Do not crush, chew, split, or dissolve tablets.

If the patient misses a dose of LYTGOBI for more than 12 hours or if vomiting occurs, resume dosing with the next scheduled dose.

The recommended dose reductions for adverse reactions are provided in Table 1.

Recommended dosage modifications for adverse reactions are provided in Table 2.

Retinal Pigment Epithelial Detachment (RPED)

LYTGOBI can cause RPED, which may cause symptoms such as blurred vision.

Among 318 patients who received LYTGOBI across clinical trials [see Adverse Reactions (6.1)] where ophthalmologic monitoring did not routinely include optical coherence tomography (OCT), RPED occurred in 9% of patients. The median time to first onset of RPED was 40 days. RPED led to dose interruption of LYTGOBI in 1.3% of patients, dose reduction in 1.6% of patients, and permanent discontinuation in 0.3% of patients.

Perform a comprehensive ophthalmological examination, including OCT of the macula, prior to initiation of therapy, every 2 months for the first 6 months, and every 3 months thereafter. For onset of visual symptoms, refer patients for ophthalmologic evaluation urgently, with follow-up every 3 weeks until resolution or discontinuation of LYTGOBI.

Withhold or reduce the dose of LYTGOBI as recommended [see Dosage and Administration (2.3)].

Dry Eye/Corneal Keratitis

Among 318 patients who received LYTGOBI across clinical trials [see Adverse Reactions (6.1)], dry eye occurred in 15% of patients. Treat patients with ocular demulcents as needed.

LYTGOBI can cause hyperphosphatemia leading to soft tissue mineralization, calcinosis, nonuremic calciphylaxis, and vascular calcification. Increases in phosphate levels are a pharmacodynamic effect of LYTGOBI [see Clinical Pharmacology (12.2)]. Among 318 patients who received LYTGOBI across clinical trials [see Adverse Reactions (6.1)], hyperphosphatemia was reported in 88% of patients based on laboratory values above the upper limit of normal. The median time to onset of hyperphosphatemia was 5 days (range 3-117). Phosphate binders were received by 77% of patients who received LYTGOBI.

Monitor for hyperphosphatemia throughout treatment. Initiate a low phosphate diet and phosphate lowering therapy when serum phosphate level is ≥5.5 mg/dL. For serum phosphate levels >7 mg/dL, initiate or intensify phosphate lowering therapy and dose reduce, withhold, or permanently discontinue LYTGOBI based on duration and severity of hyperphosphatemia [see Dosage and Administration (2.3)].

Based on findings in an animal study and its mechanism of action, LYTGOBI can cause fetal harm when administered to a pregnant woman. Oral administration of futibatinib to pregnant rats during the period of organogenesis caused fetal malformations, fetal growth retardation, and embryo-fetal death at maternal exposures lower than the human exposure at the clinical dose of 20 mg based on area under the curve (AUC).

Advise pregnant women of the potential risk to the fetus. Advise female patients of reproductive potential to use effective contraception during treatment with LYTGOBI and for 1 week after the last dose of LYTGOBI. Advise males with female partners of reproductive potential to use effective contraception during treatment with LYTGOBI and for 1 week after the last dose [see Use in Specific Populations (8.1, 8.3)].

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The pooled safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to LYTGOBI as a single agent at 20 mg orally once daily in 318 patients including 145 patients with cholangiocarcinoma and 173 patients with other advanced solid tumors. Among 318 patients who received LYTGOBI, 37% were exposed for 6 months or longer and 13% were exposed for greater than 12 months.

Previously Treated, Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

The safety of LYTGOBI was evaluated in Study TAS-120-101, which included 103 patients with previously treated, unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 fusions or other gene rearrangements [see Clinical Studies (14.1)]. Patients were treated with LYTGOBI 20 mg orally once daily until disease progression or unacceptable toxicity. The median duration of treatment was 9 months (range: 0.5 - 25 months).

Serious adverse reactions occurred in 39% of patients receiving LYTGOBI. Serious adverse reactions in ≥2% of patients who received LYTGOBI included pyrexia (3.9%), gastrointestinal hemorrhage (3.9%), ascites (2.9%), musculoskeletal pain (2.9%), and bile duct obstruction (2.9%).

Permanent discontinuation due to an adverse reaction occurred in 4.9% of patients who received LYTGOBI. Adverse reactions requiring permanent discontinuation of LYTGOBI in one patient each were esophagitis, oral dysesthesia, bile duct obstruction, dizziness, and anemia.

Dosage interruptions due to an adverse reaction occurred in 66% of patients who received LYTGOBI. Adverse reactions requiring dosage interruption in ≥5% of patients included hyperphosphatemia, palmar-plantar erythrodysesthesia syndrome, increased alanine aminotransferase, increased aspartate aminotransferase, and fatigue.

Dose reductions due to an adverse reaction occurred in 58% of patients who received LYTGOBI. Adverse reactions requiring dosage reductions in ≥2% of patients who received LYTGOBI included hyperphosphatemia, palmar-plantar erythrodysesthesia syndrome, fatigue, increased alanine aminotransferase, increased aspartate aminotransferase, nail toxicity, and stomatitis.

The most common (≥20%) adverse reactions were nail toxicity, musculoskeletal pain, constipation, diarrhea, fatigue, dry mouth, alopecia, stomatitis, abdominal pain, dry skin, arthralgia, dysgeusia, dry eye, nausea, decreased appetite, urinary tract infection, palmar-plantar erythrodysesthesia syndrome, and vomiting.

The most common laboratory abnormalities (≥20%) were increased phosphate, increased creatinine, decreased hemoglobin, increased glucose, increased calcium, decreased sodium, decreased phosphate, increased alanine aminotransferase, increased alkaline phosphatase, decreased lymphocyte, increased aspartate aminotransferase, decreased platelets, increased activated partial thromboplastin time, decreased leukocytes, decreased albumin, decreased neutrophils, increased creatine kinase, increased bilirubin, decreased glucose, increased prothrombin international normalized ratio, and decreased potassium.

Table 3 summarizes the adverse reactions in TAS-120-101. Table 4 summarizes laboratory abnormalities in TAS-120-101.

Clinically relevant adverse reactions occurring in ≤15% of patients included retinal pigment epithelial detachment (RPED, 7.8%).

Strong CYP3A Inhibitors

Avoid concomitant use of strong CYP3A inhibitors with LYTGOBI.

Futibatinib is a CYP3A substrate [see Clinical Pharmacology (12.3)]. Concomitant use of a strong CYP3A inhibitor increases futibatinib exposure [see Clinical Pharmacology (12.3)], which may increase the risk of adverse reactions.

Strong CYP3A Inducers

Avoid concomitant use of strong CYP3A inducers with LYTGOBI.

Futibatinib is a CYP3A substrate [see Clinical Pharmacology (12.3)]. Concomitant use of a strong CYP3A inducer decreases futibatinib exposure [see Clinical Pharmacology (12.3)], which may reduce the effectiveness of LYTGOBI.

Risk Summary

Based on findings in an animal study and its mechanism of action, LYTGOBI can cause fetal harm or loss of pregnancy when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data on the use of LYTGOBI in pregnant women. Oral administration of futibatinib to pregnant rats during the period of organogenesis at maternal plasma exposures below the human exposure at the clinical dose of 20 mg resulted in fetal malformations, fetal growth retardation, and embryo-fetal death (see Data ). Advise pregnant women of the potential risk to a fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data

Once daily oral administration of futibatinib to pregnant rats during the period of organogenesis resulted in 100% embryofetal mortality due to post-implantation loss at doses ≥10 mg/kg (approximately 5 times the recommended clinical dose of 20 mg based on body surface area, BSA). Fetal survival was unaffected at 0.5 mg/kg per day; however, once daily oral administration of futibatinib at the 0.5 mg/kg dose level (approximately 0.2 times the recommended clinical dose of 20 mg based on BSA) resulted in reduced mean fetal body weight and an increase in fetal skeletal and visceral malformations, major blood vessel variations, and reduced ossification.

Risk Summary

There are no data on the presence of futibatinib or its metabolites in human milk or their effects on either the breastfed child or on milk production. Because of the potential for serious adverse reactions from LYTGOBI in breastfed children, advise women not to breastfeed during treatment and for 1 week after the last dose.

LYTGOBI can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].

Pregnancy Testing

Verify pregnancy status of females of reproductive potential prior to initiating LYTGOBI [see Use in Specific Populations (8.1)].

Contraception

Females

Advise females of reproductive potential to use effective contraception during treatment with LYTGOBI and for 1 week after the last dose.

Males

Advise males with female partners of reproductive potential or who are pregnant to use effective contraception during treatment with LYTGOBI and for 1 week after the last dose.

The safety and effectiveness of LYTGOBI have not been established in pediatric patients.

Animal Toxicity Data

In 4- or 13-week repeat-dose toxicology studies in adult rats and dogs, findings included increased inorganic phosphorus and calcium in plasma, ectopic mineralization in various organs and tissues, and lesions in bone/cartilage at futibatinib exposures lower than the human exposure at the clinical dose of 20 mg. Findings in rats also included corneal lesions. Evidence of recovery in rats and dogs was observed four weeks after cessation of dosing except for the ectopic mineralization.

Of the 103 patients treated with LYTGOBI in Study TAS-120-101, 22% were 65 years or older. Based on available data, no overall differences in safety or effectiveness of LYTGOBI have been observed between patients 65 years of age and older and younger adult patients.

There are limited data in patients treated with LYTGOBI with total bilirubin >1.5🞨 ULN, and patients with cholangiocarcinoma with total bilirubin >3🞨 ULN were excluded from enrollment in clinical trials. Patients with cirrhosis and total bilirubin >1.5🞨 ULN to 3🞨 ULN may have the potential for increased adverse reactions compared to patients with normal hepatic function due to higher unbound futibatinib exposure [see Clinical Pharmacology (12.3)].

Futibatinib is a small molecule kinase inhibitor of FGFR 1, 2, 3, and 4 with IC₅₀ values of less than 4 nM. Futibatinib covalently binds FGFR. Constitutive FGFR signaling can support the proliferation and survival of malignant cells. Futibatinib inhibited FGFR phosphorylation and downstream signaling and decreased cell viability in cancer cell lines with FGFR alterations including FGFR fusions/rearrangements, amplifications, and mutations. Futibatinib demonstrated anti-tumor activity in mouse and rat xenograft models of human tumors with activating FGFR genetic alterations.

Serum Phosphate

Futibatinib increased serum phosphate levels due to FGFR inhibition. Serum phosphate increased with increasing futibatinib exposure across the dose range of 4 to 24 mg orally once daily (0.2 to 1.2 times the recommended dose), with increased risk of hyperphosphatemia at higher futibatinib exposure.

Cardiac Electrophysiology

At four times the approved recommended dose, LYTGOBI does not cause clinically significant QTc interval prolongation.

The pharmacokinetics of futibatinib were observed at steady state in patients with advanced solid tumors unless otherwise specified at the approved recommended dosage and are presented as mean (%CV) unless otherwise specified.

Futibatinib maximum concentration (C_max) is 144 mg/mL (50%) and systemic exposure (AUC) is 790 ng∙hr/mL (45%). Futibatinib exposure (AUC) increased in dose proportional manner over the dose range from 4 to 24 mg orally once daily (0.2 to 1.2 times the approved recommended dosage). No accumulation is observed at steady state.

Absorption

Futibatinib median (min, max) time to maximum plasma concentration (T_max) is 2 hours (1.2, 23 hours).

Effect of Food

Futibatinib C_max decreased by 42% with no clinically significant differences in AUC in healthy subjects following administration of LYTGOBI with a high-fat and high-calorie meal (900 to 1000 calories with approximately 50% from fat).

Distribution

The apparent (oral) volume of distribution is 66 L (18%). Futibatinib plasma protein binding is 95%, primarily to albumin and α1-acid glycoprotein.

Elimination

Futibatinib elimination half-life is 2.9 hours (27%) with an apparent (oral) clearance of 20 L/hr (23%).

Metabolism

Futibatinib is primarily metabolized by CYP3A and to a lesser extent by CYP2C9 and CYP2D6. Unchanged futibatinib accounts for 59% of radioactivity in plasma in healthy subjects.

Excretion

Following a single oral dose of radiolabeled futibatinib 20 mg, approximately 91% of the dose was recovered in feces and 9% in urine.

Specific Populations

No clinically significant differences in the pharmacokinetics of futibatinib were observed based on age (18 to 82 years), sex, race (White, Asian, and African American), body weight (36 to 152 kg), or creatinine clearance (CLcr) 30 to 89 mL/min (estimated by Cockcroft-Gault). The effect of CLcr of 15 to 29 mL/min or renal dialysis in end-stage renal disease (CLcr <15 mL/min) on futibatinib pharmacokinetics is unknown.

Patients with Hepatic Impairment

No clinically significant differences in the pharmacokinetics of futibatinib were observed in subjects with mild hepatic impairment (total bilirubin ≤ ULN and AST > ULN or total bilirubin >1 to 1.5🞨 ULN and any AST or Child-Pugh A) or moderate to severe hepatic impairment (Child-Pugh B to C) with total bilirubin < 1.5 🞨 ULN. The effect of moderate to severe hepatic impairment without cirrhosis on futibatinib pharmacokinetics is unknown.

In subjects with cirrhosis and total bilirubin >1 to 1.5🞨 ULN, mean unbound futibatinib AUC and C_max increased by 1.7-fold relative to subjects with normal hepatic function. In subjects with cirrhosis and total bilirubin >1.5🞨 ULN, mean unbound futibatinib AUC and C_max increased by 3.2-fold and 2.4-fold, respectively, compared to values in healthy subjects.

Drug Interaction Studies

Clinical Studies

Strong CYP3A inhibitors: Futibatinib C_max increased by 1.5-fold and AUC by 1.4-fold following concomitant use of multiple doses of itraconazole (strong CYP3A inhibitor).

Strong CYP3A inducers: Futibatinib C_max decreased by 53% and AUC by 64% following concomitant use of multiple doses of rifampin (strong CYP3A inducer).

Other Drugs: No clinically significant differences in futibatinib pharmacokinetics were observed with concomitant use of multiple doses of quinidine (P-gp inhibitor) or lansoprazole (proton pump inhibitor).

No clinically significant differences in the pharmacokinetics of the following drugs were observed following concomitant use of multiple doses of LYTGOBI: midazolam (CYP3A substrate), digoxin (P-pg substrate), and rosuvastatin (BCRP substrate).

In Vitro Studies

CYP Enzymes: Futibatinib does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 and does not induce CYP1A2 or CYP2B6.

Transporter Systems: Futibatinib is not a substrate of OATP1B1 or OATP1B3. Futibatinib does not inhibit OAT1, OAT3, OCT2, OATP1B1, OATP1B3, MATE1, or MATE2K.

Carcinogenicity studies have not been conducted with futibatinib.

Futibatinib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay. Futibatinib was clastogenic in an in vitro chromosomal aberration assay. Futibatinib was not clastogenic in a rat bone marrow micronucleus assay or a rat DNA damaging (Comet) assay.

Dedicated fertility studies with futibatinib have not been conducted.

TAS-120-101 (NCT02052778), a multicenter, open-label, single-arm trial, evaluated the efficacy of LYTGOBI in 103 patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma. The presence of FGFR2 fusions or other rearrangements was determined in 102 enrolled patients (99%) using next generation sequencing (NGS) testing. Qualifying in-frame fusions and other rearrangements were predicted to have a breakpoint within intron 17/exon 18 of the FGFR2 gene leaving the FGFR2 kinase domain intact.

Patients received LYTGOBI at a dosage of 20 mg orally once daily until disease progression or unacceptable toxicity. The major efficacy outcome measures were overall response rate (ORR) and duration of response (DoR) as determined by an independent review committee (IRC) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

The trial population characteristics were: Median age was 58 years (range: 22 to 79 years) with 22% of patients ≥65 years, 56% were female, race was: 50% White, 29% Asian, 8% Black or African American, 1% Native Hawaiian or Other Pacific Islander, 13% unknown, baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 (47%) or 1 (53%). Seventy-eight percent (78%) of patients had in-frame FGFR2 gene fusions and the most commonly identified FGFR2 fusion partner was BICC1 (n=24, 23%). Twenty-two percent (22%) of patients had other FGFR2 rearrangements that may not be in-frame with the partner gene or the partner gene was not identifiable.

All patients had received at least 1 prior systemic therapy, 30% had 2 prior lines of therapy, and 23% had 3 or more prior lines of therapy. All patients received a prior platinum-based therapy including 91% with prior gemcitabine/cisplatin.

Efficacy results are summarized in Table 5. The median time to response was 2.5 months (range 0.7 – 7.4 months).